We provide access to the latest international treatment protocols: personalized mRNA vaccines, Lutetium Lu-177 and Actinium Ac-225 therapy, proton therapy, and organ-preserving surgery under the supervision of government hospitals affiliated with the Russian Ministry of Health.
Request Case EvaluationA detailed explanation of treatment mechanisms and the competitive advantages of Russian medicine in accordance with the approved profile.
A revolutionary genetic technology based on reading the complete genetic code of the patient’s malignant tumor. The DNA and RNA sequences of the cancer cell are extracted and its unique “protein mutations” are identified. Based on this, a personalized and optimized mRNA strand is manufactured and injected into the patient, training immune cells (T-cells) to immediately and selectively recognize only these mutations, attack the cancer cells, and eradicate them at their roots without causing harm to healthy tissues.
While the United States and European countries remain limited to slow clinical trials surrounded by regulatory complexities, Russia has uniquely become the first and only country in the world to introduce personalized mRNA-based cancer vaccines into actual clinical application. The treatment is currently available within government hospitals affiliated with the Russian Ministry of Health for melanoma, according to specific selection criteria and medical requirements designed to ensure the highest response rates.
It is used as a personalized immunotherapy line to prevent lethal cancer recurrence and eliminate hidden microscopic foci after or during the primary treatment protocol.
Access to the very latest achievement in human medicine in the only country that actually provides it to patients, at a carefully structured and guaranteed economical cost away from commercial exploitation by Western companies.
Treatment uses molecularly targeted nuclear medicine with Lutetium (Lu-177 PSMA) and Actinium (Ac-225). The radioactive isotope is linked to a molecule that selectively targets PSMA receptors, which are densely present on the surface of prostate cancer cells. After injection, these molecules travel like guided missiles, bind to the cancer cell, and release precise microscopic radiation that destroys the DNA strand inside the tumor, even in cases of advanced bone and lymphatic spread.
These treatments are administered within government hospitals affiliated with the Russian Ministry of Health, relying on nuclear reactors for medical purposes that locally produce high-purity radioisotopes, particularly Actinium (Ac-225), which is in severe global shortage. This ensures immediate availability of therapeutic doses without long waiting lists that could endanger the patient’s life.
Targeted molecular therapy (Radioligand Therapy) for advanced and hormone-resistant cases, or precision robotic surgery for early-stage cases.
The cost of a radioisotope treatment cycle in Moscow is 50%–65% lower than in European and American centers, using the same isotopes under the supervision of internationally recognized nuclear medicine specialists.
Direct brachytherapy and proton therapy techniques are used. Precision radioactive plaques are custom-made to fit the eye and fixed with millimeter accuracy over the tumor to concentrate the radiation dose on cancer cells and destroy them without affecting healthy tissues or the optic nerve.
Government hospitals affiliated with the Russian Ministry of Health are a leading global reference in the organ-preserving school of ophthalmology and eye surgery. While conventional protocols in many countries tend toward complete removal of the eyeball (Enucleation) in advanced cases, these hospitals have decades of experience in preserving both the eye as an organ and visual function.
Targeted radiation application at microscopic sites combined with laser thermal coagulation techniques.
A rare opportunity to save the eye from complete surgical removal at a treatment cost up to 70% lower than Western centers.
Advanced surgical and immunotherapy protocols are applied, such as organ-preserving robotic laparoscopic surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC), in which the abdominal cavity is washed with heated chemotherapy doses after tumor removal to eliminate any free-floating cells.
The surgical school in government hospitals affiliated with the Russian Ministry of Health places strict emphasis on the patient’s quality of life. The surgeons’ first objective is to avoid a “permanent external stoma” (Colostomy); these hospitals have the expertise and technologies needed to reconnect the bowel with high precision even in tumors located very close to the anus.
Advanced laparoscopic resection preserving the anal sphincter, with targeted immunotherapy before and after surgery.
Natural bowel reconnection success rates exceed 92%, with comprehensive prices for surgery, intensive care, and rehabilitation that are significantly lower than in neighboring countries.
Treatment relies on proton therapy combined with precision microsurgery and neuronavigation systems. Proton beams are characterized by the “Bragg peak,” releasing their full destructive energy only within the tumor focus and stopping immediately without radiation spill into surrounding tissues responsible for speech, movement, or memory.
Government hospitals affiliated with the Russian Ministry of Health provide advanced proton therapy complexes equipped with modern particle accelerators, along with specialized surgical teams experienced in complex skull-base tumors and gliomas (Glioblastoma).
Adaptive microsurgical resection followed by proton therapy to destroy hidden tumor roots and prevent recurrence.
Complex proton therapy is available at a cost as low as half the established cost in Europe and the United States.
Stereotactic body radiotherapy (SBRT) is used in combination with genetic and targeted therapy. The systems deliver highly concentrated radiation doses from multiple angles that converge with extreme precision on the lung tumor focus, causing it to shrink and die without the need to open the chest wall.
Government hospitals affiliated with the Russian Ministry of Health excel in “respiratory motion tracking during radiation” (4D-RT), where the system adapts to lung movement during inhalation and exhalation to ensure that only the tumor is targeted and healthy lung tissue is spared.
Non-invasive radiosurgery for early cases, or a combination of immunotherapy and video-assisted thoracic surgery (VATS) for advanced cases.
Access to the latest genetic and targeted therapies and comprehensive thoracic care at competitive economical prices.
Treatment is based on targeted therapy guided by genetic testing of the tumor (HER2, ER, PR), combined with organ-preserving oncoplastic surgery that removes the tumor with safety margins and immediately reconstructs the breast in the same operation using the patient’s own tissue or customized implants.
The treatment concept in government hospitals affiliated with the Russian Ministry of Health rejects sacrificing a woman’s aesthetic appearance; tumor removal and cosmetic reconstruction are performed as one integrated step under a joint team of oncology and plastic surgeons.
Preoperative hormonal/targeted therapy to shrink the tumor, followed by organ-preserving resection and immediate reconstruction.
Oncologic and reconstructive surgery are performed in a single operation at a cost 60% lower than performing them separately in Western countries.
Treatment relies on dose-intensive chemotherapy protocols and targeted immunotherapy, followed by stem cell transplantation (Bone Marrow / Stem Cell Transplantation), either autologous or donor-derived.
Government hospitals affiliated with the Russian Ministry of Health include advanced hematology departments that use sophisticated stem-cell purification techniques and have extensive banks and rapid genetic matching coverage, reducing graft rejection rates and increasing rates of complete recovery.
Targeted immunotherapy followed by stem cell transplantation to rebuild a fully healthy hematopoietic and immune system.
Stem cell transplantation procedures in Russia are among the safest and most economical worldwide, with costs 50%–70% lower than American and European centers.
Intraoperative radiotherapy (IORT) and custom-made prosthetic joints produced by 3D printing (3D-Printed Custom Implants) are used to reconstruct resected bones and joints.
The Russian orthopedic surgical school applied in government hospitals affiliated with the Russian Ministry of Health focuses on “limb salvage” and prevention of amputation as a top priority by manufacturing metallic joint and bone replacements precisely matched to the patient’s anatomy.
Preoperative chemotherapy followed by tumor resection and implantation of a 3D bone replacement without the need for limb amputation.
Manufacture of 3D joints and replacements and motor rehabilitation at a very low cost compared with the price of medical implants in the West.
Targeted radioembolization (Radioembolization – SIRT) and chemoembolization (TACE) are applied. A fine catheter is introduced through the arteries directly to the tumor in the liver or pancreas to inject a very high concentration of radioactive or chemotherapeutic material while cutting off the tumor’s blood supply and starving it.
Government hospitals affiliated with the Russian Ministry of Health have highly precise interventional catheterization technologies that allow access to the most difficult arteries feeding pancreatic and liver tumors, converting inoperable tumors into resectable tumors.
Direct arterial radioembolization combined with thermal ablation or interventional surgical resection.
Interventional catheter procedures for tumors at very appropriate prices, with high safety rates and rapid rehabilitation.
Send the patient’s complete medical file, including recent reports, biopsy and histopathology results, CT / MRI / PET-CT scans, laboratory tests, previous treatments, and the results of response to those treatments.
After receiving the complete medical file and payment of the review fee, the case is referred for specialized medical review, and the medical report is usually issued within 3–5 working days.